-
Journal of Immunological Methods Jun 1996This paper is the first report on the use of an idiotype-anti-idiotype monoclonal antibody reaction to develop an enzyme immunoassay for thyroxine (T4). We have...
This paper is the first report on the use of an idiotype-anti-idiotype monoclonal antibody reaction to develop an enzyme immunoassay for thyroxine (T4). We have developed a monoclonal antibody against T4, named 1F10 of IgG1 subclass and KA 5.21 x 10(8) M-1 which was used to obtain anti-idiotypic monoclonal antibodies. Anti-idiotypic antibodies were selected by a novel method, a passive agglutination assay with the idiotype monoclonal 1F10 absorbed on latex particles and subsequently characterized by RIA. One of these anti-idiotype antibodies, named 5B3--type beta antibody--of IgG1 subclass, was used to develop an enzyme-linked T4 idiotype-anti-idiotype immunosorbent assay. The T4 calibration curve, using the 1F10 idiotypic antibody adsorbed to solid phase and the 5B3 anti-idiotypic antibody conjugated to alkaline phosphatase (ALP), shows adequate performance in the range between 0.7-25 micrograms% of the analyte. The reliability of the proposed method is demonstrated by the correlation coefficient r = 0.74, found between T4 measured by RIA and our assay, with a panel of sera from euthyroid, hypothyroid and hyperthyroid individuals. The correlation coefficient was r = 0.93 within assays and r = 0.88 between assays. These results provide the basis for a new non isotopic assay for the study and diagnosis of T4-related human disease and provides a model to develop immunoassays for other haptens and small molecules of clinical interest.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Affinity; Enzyme-Linked Immunosorbent Assay; Female; Immunoglobulin Idiotypes; Mice; Mice, Inbred BALB C; Thyroxine
PubMed: 8699024
DOI: 10.1016/0022-1759(96)00023-3 -
Biologicals : Journal of the... Nov 2013Pasteurella multocida was isolated from cattle affected with haemorrhagic septicaemia and characterized on the basis of morphological, cultural and biochemical tests....
Pasteurella multocida was isolated from cattle affected with haemorrhagic septicaemia and characterized on the basis of morphological, cultural and biochemical tests. Bacterial outer membrane proteins (OMPs) were extracted with 1% Sarkosyl method. P. multocida anti-idiotype vaccine prepared from OMPs (21.3 mg per 100 ml), was evaluated and compared with bacterin supplemented with 10% OMPs and plain alum-adsorbed bacterin in rabbit models. It was observed that OMPs-anti-idiotype vaccine induced high levels of antibody titres (geomean titres -GMT) detected using indirect haemagglutination (IHA) test. The OMPs anti-idiotype antibody titres of 168.9 GMT were obtained to 42.2 GMT in OMPs supplemented bacterin on 21 days post vaccination, while the plain bacterin had the least titre of 27.9 GMT. The OMPs-anti-idiotype vaccine provoked better immunogenic response in terms of highest GMT titres and long lasting effect in rabbits and 100% protection against the challenge with homologous strain of P. multocida,while 88% protection was obtained in rabbits, given OMPs supplemented bacterin.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Vaccines; Cattle; Hemagglutination Tests; Hemorrhagic Septicemia; Male; Pasteurella multocida; Rabbits; Serotyping; Time Factors; Vaccination
PubMed: 23830882
DOI: 10.1016/j.biologicals.2013.05.003 -
Journal of Immunological Methods May 1985An enzyme-linked immunosorbent assay (ELISA) to detect anti-idiotype (Id) antibody is described. Using this assay auto-anti-Id was detected in the serum of aged mice...
An enzyme-linked immunosorbent assay (ELISA) to detect anti-idiotype (Id) antibody is described. Using this assay auto-anti-Id was detected in the serum of aged mice immunized with 2,4,6-trinitrophenylated-Ficoll (TNP-F). Hapten eluates from anti-TNP-F immune spleen cells also contained readily detectable auto-anti-Id.
Topics: Aging; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Formation; Autoantibodies; Enzyme-Linked Immunosorbent Assay; Hybridomas; Immunoglobulin Idiotypes; Male; Mice; Trinitrobenzenes
PubMed: 3873501
DOI: 10.1016/0022-1759(85)90103-6 -
Seminars in Oncology Oct 2002Malignant melanoma remains a difficult clinical problem. Chemotherapy is not effective and immunotherapy has long been contemplated as the preferred approach to this... (Review)
Review
Malignant melanoma remains a difficult clinical problem. Chemotherapy is not effective and immunotherapy has long been contemplated as the preferred approach to this disease. Extensive passive and active immunotherapy trials have been conducted. Active vaccination with whole cells or defined antigens, administered with a panoply of techniques to increase immunogenicity, has yielded inconsistent results. The development of antibody-based vaccines has allowed vaccination without the need for tumor tissue material or purified antigens. The idiotype network theory originally proposed by Lindemann and by Jerne provided the basis for the development of anti-idiotype (anti-Id) antibody vaccines, which mimic the internal image of the epitope targeted for immunization. Preclinical and phase I clinical data are available for various malignancies. In melanoma, some of the anti-Id vaccines have targeted gangliosides. One of these vaccines, TriGem, has been successful in generating a robust and specific humoral immunity in melanoma patients. Phase II data suggest this anti-Id vaccine has clinical activity.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibody Formation; Antigens, Neoplasm; Cancer Vaccines; Humans; Melanoma
PubMed: 12407511
DOI: 10.1053/sonc.2002.35241 -
Cancer Science Jan 2011Gangliosides have been considered as potential targets for immunotherapy because they are overexpressed on the surface of melanoma cells. However, immunization with...
The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Gangliosides have been considered as potential targets for immunotherapy because they are overexpressed on the surface of melanoma cells. However, immunization with purified gangliosides results in a very poor immune response, usually mediated by IgM antibodies. To overcome this limitation, we immunized mice with R24, a monoclonal antibody (mAb) that recognizes the most tumor-restricted ganglioside (GD3); our goal was to obtain anti-idiotype (Id) antibodies bearing the internal image of GD3. Animals produced anti-Id and anti-anti-Id antibodies. Both anti-Id and anti-anti-Id antibodies were able to inhibit mAb R24 binding to GD3. In addition, the anti-anti-Id antibodies were shown to recognize GD3 directly. Anti-Id and anti-anti-Id mAb were then selected from two fusion experiments for evaluation. The most interesting finding emerged from the characterization of the anti-anti-Id mAb 5.G8. It was shown to recognize two different GD3-expressing human melanoma cell lines in vitro and to mediate tumor cell cytotoxicity by complement activation and antibody-dependent cellular cytotoxicity. The biological activity of the anti-anti-Id mAb was also tested in a mouse tumor model, in which it was shown to be a powerful growth inhibitor of melanoma cells. Thus, activity of the anti-anti-Id mAb 5.G8 matched that of the prototypic anti-GD3 mAb R24 both in vitro and in vivo. Altogether, our results indicate that the idiotype approach might produce high affinity, specific and very efficient antitumor immune responses.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Neoplasm; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Female; Gangliosides; Humans; Immunization; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL
PubMed: 21070480
DOI: 10.1111/j.1349-7006.2010.01771.x -
Journal of Immunology (Baltimore, Md. :... Feb 1986An initial panel of four syngeneic monoclonal antibodies directed against the idiotype of a murine B cell lymphoma was used to treat this tumor in vivo. The antibody in...
An initial panel of four syngeneic monoclonal antibodies directed against the idiotype of a murine B cell lymphoma was used to treat this tumor in vivo. The antibody in the panel of the IgG2a isotype was more effective in treatment than the other antibodies, which were of the IgG1 and IgG2b isotypes. To independently assess the role of antibody isotype in mediating antitumor effects, switch variant hybridoma families were isolated from the hybridomas secreting the less effective IgG1 and IgG2b antibodies. A family isolated from an IgG1-secreting parent consisted of IgG1-, IgG2b-, and IgG2a-secreting members, and an IgG2a variant was isolated from an IgG2b-secreting parent for another family. Antibody members of each family differed only in heavy chain composition and were the same with respect to their light chains and their affinity and specificity for idiotype. The IgG2a members of both families were superior to the other members in inhibiting tumor growth with an order of effectiveness of IgG2a greater than IgG1 greater than IgG2b. These in vivo results paralleled the abilities of these different isotype antibodies to mediate antibody-dependent cellular cytolysis in vitro. For the IgG2b----IgG2a family, in vivo treatment with the IgG2a member given i.p. after i.p. tumor challenge at one-tenth the dose of the IgG2b member was still superior to the latter. At one-hundredth the dose of the IgG2b, the IgG2a was still superior to the latter when the antibodies were given i.p. and tumors subcutaneously. These data and those showing that the clearance of these antibodies from the serum differed in only a relatively minor way indicate that the IgG2a antibodies in this system had greater antitumor effects primarily by virtue of their greater capacity for host effector interaction.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; B-Lymphocytes; Cell Line; Genetic Variation; Hybridomas; Immunoglobulin Allotypes; Immunoglobulin G; Immunoglobulin Idiotypes; Lymphoma; Mice; Mice, Inbred C3H
PubMed: 3484499
DOI: No ID Found -
Igaku Kenkyu. Acta Medica Feb 1992A human monoclonal antibody, ll-50 (IgM, lambda), was generated, which reacted specifically with a major of glycolipid present in LS174T colon cancer cells. The...
A human monoclonal antibody, ll-50 (IgM, lambda), was generated, which reacted specifically with a major of glycolipid present in LS174T colon cancer cells. The glycolipid antigen which reacted with the ll-50 antibody was expected to four sugar residues from its TLC mobility, and it was ascertained that the glycolipid antigen which reacted with ll-50 antibody might be Lc4 antigen [Gal beta 1----3 GLcNAc beta 1----3 Gal beta 1----4 Glc beta 1----1 Cer] judging from TLC immunostaining and ELISA when the reactivity of ll-50 antibody was tested using various pure glycolipids in 3-5 sugar residues as an antigen. Sera in patients with malignant disorders and healthy individuals were analyzed by Sandwich assay of immobilized and biotinylated ll-50 antibody. The serum of the Lc4 antigen recognized by ll-50 antibody was significantly higher in patients with malignant disorders than that in healthy individuals (p less than 0.05). Three mouse monoclonal anti-idiotype antibodies, G3, B3 and C5 (all IgG1), were generated by the immunization of BALB/c mice with ll-50 antibody. These anti-idiotype antibodies specifically bound to to human monoclonal antibody, ll-50 and had a significant inhibitory activity towards the binding of ll-50 antibody to the Lc4 antigen. This indicated that these anti-idiotype antibodies, G3, B3, and C5, were paratope-related anti-idiotype antibodies. G3, B3, and C5 were expected to define the nearest idiotope because they could mutually inhibit ll-50 antibody. Sera in patients with malignant disorders and healthy individuals were analyzed by Sandwich assay of immobilized and biotinylated anti-idiotype antibodies, G3, B3, and C5. As to the ll-50 like antibodies defined by C5 (Id-C5+), the mean serum level in patients with malignant disorders was significantly higher than that in healthy individuals (p less than 0.05). As to the ll-50 like antibodies defined by B3 (Id-B3+), the mean serum level in patients with malignant disorders was significantly higher than that in healthy individuals.(ABSTRACT TRUNCATED AT 400 WORDS)
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Binding Sites, Antibody; Binding, Competitive; Colonic Neoplasms; Enzyme-Linked Immunosorbent Assay; Glycolipids; Humans; Hybridomas; Immunoglobulin M; Mice
PubMed: 1523940
DOI: No ID Found -
American Journal of Veterinary Research May 1996To evaluate the humoral response of horses to vaccination, using a murine monoclonal anti-idiotypic antibody (A4) that shares an epitope with lipid A.
OBJECTIVE
To evaluate the humoral response of horses to vaccination, using a murine monoclonal anti-idiotypic antibody (A4) that shares an epitope with lipid A.
DESIGN
Serum concentrations of antilipid A antibody and 1C9 (epitope on murine monoclonal antilipid A antibody) were measured serially during the period of vaccination with A4.
ANIMALS
6 clinically normal adult ponies.
PROCEDURE
Ponies were inoculated IM 3 times at monthly intervals with A4. Two weeks after each inoculation, serum was obtained and was assayed by ELISA for antilipid A and 1C9 concentrations. Additional vaccinations were given to 2 of the ponies after a several-month rest period.
RESULTS
There was significant increase in 1C9 concentration (P < 0.0001) during the period of vaccination and a trend toward increased antilipid A concentration. The latter effect was not significant (P = 0.055). Additional vaccinations produced further increase in serum 1C9 concentration; antilipid A concentration increased in one of these ponies but not the other. Maximal antilipid A concentration recorded in these ponies was approximately 6 times preimmune concentration and was comparable to that found in a commercial antiendotoxin antiserum. 1C9 also was detected in the commercial antiserum.
CONCLUSIONS
A4 anti-idiotype vaccination of horses is safe and may be effective in eliciting an antibody response against endotoxin. The finding of 1C9 in a commercial antiendotoxin antiserum indicates that this idiotype may be part of the normal polyclonal antibody response of horses to endotoxin.
CLINICAL RELEVANCE
It may be possible to use anti-idiotypic antibody vaccination in horses to induce protection against the effects of endotoxin.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Endotoxins; Enzyme-Linked Immunosorbent Assay; Epitopes; Horses; Immune Sera; Lipid A; Male; Mice; Vaccines
PubMed: 8723877
DOI: No ID Found -
European Journal of Immunology Apr 1974
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Bacterial; Antibody Formation; Antibody Specificity; Bacterial Vaccines; Electrophoresis; Female; Hemolysis; Immunoglobulins; Isoelectric Focusing; Lymphocytes; Mice; Mice, Inbred A; Radiation Chimera; Species Specificity; Spleen; Streptococcus
PubMed: 4546826
DOI: 10.1002/eji.1830040413 -
The Journal of Experimental Medicine Nov 1975Anti-idiotypic antibodies have been used to mimic antigen in the mouse antiphosphorylcholine response in order to investigate the induction of precursors of...
Anti-idiotypic antibodies have been used to mimic antigen in the mouse antiphosphorylcholine response in order to investigate the induction of precursors of antibody-forming cells. We have shown that interaction of anti-idiotype antibody with receptor antibody molecules induces the formation of antibodies that are specific for phosphorylcholine and carry the idiotypic determinants. This induction is dependent on the recognition of carrier determinants on the anti-idiotype antibody by helper T cells. We conclude that receptor antibody molecules on the surface of the precursors of antibody-forming cells deliver the antigenic signal for the induction of these cells.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibody Formation; Antibody Specificity; Antibody-Producing Cells; Binding Sites, Antibody; Cells, Cultured; Choline; Epitopes; Immunoglobulins; Mice; Mice, Inbred Strains; Phosphorylcholine; Spleen; T-Lymphocytes
PubMed: 53257
DOI: 10.1084/jem.142.5.1121